The Role of Metabotropic Glutamate Receptors in Health and Disease
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Metabolism".
Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 40908
Special Issue Editors
Interests: mglu5 receptor; GABAergic neurons; amygdala; metabotropic glutamate receptor
Special Issue Information
Dear Colleagues,
Thirty years ago, Shigetada Nakanishi and his group at Kyoto University (Japan) identified the molecular structure of metabotropic glutamate (mGlu) receptors by cloning the first of this receptor family (mGlu1), which followed the discovery, a lustrum before, that glutamate could activate receptors coupled to G proteins, a finding made independently by the group of Joel Bockaert in Montpellier and the one of Erminio Costa in Washington. This discovery, as with many other neurotransmitter receptors, paved the way for a large number of ensuing studies investigating the anatomical distribution and physiological functions of these receptors. A lot of pharmacological agents modulating the activity of mGlu receptors have also been developed and tested to examine the role of these receptors in many biological processes and their potential involvement in neuropsychiatric diseases using primarily animal models. Several clinical studies have further explored the efficacy of drugs acting on mGlu receptors as disease modifiers, but in spite of these intense efforts by both academic researchers and the pharmaceutical industry, none have yet reached the market. These endeavors, on the other hand, have bolstered the relevance that mGlu receptors play in physiological processes and their potential as druggable candidates to cure diseases. Hence, renewed efforts are needed to provide novel mechanistic insights into the function of these receptors and of their translational value for human diseases.
In this Special Issue, we invite you to improve our current knowledge of mGlu receptors by contributing original research articles on any aspect of their expression, function, and regulation in both health and disease. Stimulating reviews that critically appraise or provide new interpretations of the extant literature are also highly welcomed.
Prof. Dr. Francesco Ferraguti
Dr. Ferdinando Nicoletti
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- metabotropic glutamate receptor
- psychopharmacology
- intracellular signaling
- allosteric modulators
- synaptic transmission
- plasticity